1.Effect of budesonide inhalation joint montelukast in the treatment of children with mycoplasma pneumonia cough
Chinese Journal of Primary Medicine and Pharmacy 2016;23(8):1211-1214
Objective To observe the effect of budesonide inhalation joint montelukast in the treatment of children with mycoplasma pneumonia cough.Methods 176 children with mycoplasma pneumonia cough were chosen.According to the order of admission,they were divided into observation group and control group.Control group was given montelukast sodium chewable tablets treatment,the observation group was given budesonide inhalation on the basis of treatment of control group.After treatment,the efficacy,prognosis and compliance were observed.Results Before treatment,the cough scores between the two groups had no significant difference (P>0.05).After treatment, the degree of cough in the two groups were significantly improved, the cough score of the observation group from (7.4 ±2.2)points decreased to (1.5 ±0.6)points (t=24.271,P<0.05);the cough score of the control group from (7.5 ±2.3)points decreased to (5.4 ±1.8)points (t=6.745,P<0.05);and the cough score of the observation group was significantly lower than the control group,the difference was statistically significant (t =19.282,P <0.05).The total effective rate of the observation group was 93.18%,which of the control group was 73.86%,the difference was statistically significant (χ2 =3.446,P<0.05).The incidence rate of adverse reactions in the observa-tion group was 4.55%,which in the control group was 11.36%,but there was no significant difference between two groups (P>0.05).The relapse rate of the observation group was 7.95%,which was significantly lower than 18.18%of the control group, the difference between the two groups was statistically significant ( P <0.05 ) .Conclusion Budesonide inhalation joint montelukast in the treatment of mycoplasma pneumonia cough has significant effect,it has less adverse effects,good safety,and children without any discomfort,so it worthy of clinical application.
2.Clinical characteristics and treatment outcome of 145 cases with multiple myositis and dermatomyositis
Yanhua WANG ; Lingfei MO ; Jing LUO ; Jing ZHANG ; Xiuyuan FENG ; Dan PU ; Zhingming HAO ; Lan HE
Chinese Journal of Rheumatology 2016;(2):116-120
Objective To investigate the clinical characteristics of patients with polymyositis(PM) and dermatomyositis (DM), and compare the differences of PM/DM to help the understanding of clinical diagnosis and treatment. Methods One hundred and forty-five hospitalized PM/DM patients from Department of Rheumatology of the First Affiliated Hospital of Xiˊan Jiaotong University were collected from May 2008 to December 2014, and the clinical manifestations, muscle enzymes, electromyogram, muscle biopsy, treatment outcome were retrospectively analyzed. Mann-Whitney U test and χ2 test were used for statistical analysis. Results The most common initial symptom of PM was muscle weakness, accounted for 51.2%, while rash was the initial presentation in most DM patients(43.1%). The incidence of interstitial lung disease (ILD) (62.7% vs 39.5%, χ2=11.009, P=0.001), and the elevation of CRP (48.9% vs 26.8%, χ2=10.272, P=0.001) were all higher in DM than PM, while the elevation of level of CK (85.4% vs 61.8%, U=-2.668, P=0.008) and CKMB (82.9%vs 41.2%, U=-3.303, P=0.001) were more common in PM compared with DM. The pathological study showed degeneration of muscle fiber, connective tissue hyperplasia in most PM patients, and perimysium atrophy, vacuoles degeneration, muscle bundles, perivascular inflammatory cell infiltration were observed in most DM patients. During the follow-up, the clinical remission rate was 57.5%, the relapse rate and the mortality rate was 7.5%and 31.1%respectively. The mortality rate was higher in DM than PM (34.6% vs 21.4%, χ2=4.861, P=0.027). Infection and tumors were the major causes of death, and the lung was the most common site of infection. Conclusion Differences in the clinical features, muscle enzymes, CRP level, pathology and the mortality rate between PM and DM are evident, while ILD, infection and the higher mortality rate are more common in DM than in PM.
3.Peripheral regulatory T cells in systemic lupus erythematosus patients: the relationship with organ damage and the influence of treatment regimens
Zijing YIN ; Li ZHU ; Nan HU ; Xiuyuan FENG ; Jing LUO ; Jing WANG ; Bomiao JU ; Dan PU ; Xiaohong LV ; Lan HE
Chinese Journal of Rheumatology 2018;22(10):664-671,后插1
Objective To explore the distribution characteristics and function of peripheral regulatory T cells (CD4+CD25+Foxp3+T cells) in patients with systemic lupus erythematosus (SLE).In addition,we analyzed the relationship between peripheral regulatory T cells and organ damage and the influence of different treatment regimens on them.Methods Two hundred and six SLE patients and 38 healthy volunteers were enrolled,which included 12 patients with untreated new-onset lupus,11 patients with drug withdrawal more than six months and 183 patients with treatments.Phenotypic and functional analysis of peripheral blood CD4+CD25+Foxp3+T cells were performed by flow cytometry.The correlations of CD4+CD25+Foxp3+ T cells with disease activity,organ involvement were analyzed.Thealtered frequency of CD4+CD25 +Foxp3+T cells under different treatment regimens was compared.Statistical Package form Soci-science (SPSS) 21.0 software was used for data analysis,Student's t test,one-way ANOVA,Mann-Whitney T test,Kruskal-Wallis test,Chi-square test,Simple linear correlation analysis was used.Results CD4 +CD25 +Foxp3 + T cells were significantly increased inactive SLE patients [1 1.9% (9.3%,16.0%),mean difference =104.71,P<0.01] and inactive SLE patients [11.0%(7.7%,14.7%),mean difference=86.10,P<0.01] compared with healthy controls [6.1%(5.3%,7.4%)].CD4+CD25+Foxp3+T cellsshowed sign-ificantly positive correlations with SLEDAI-2K (r=0.191,P<0.05),dsDNA (r=0.262,P<0.05),ESR (r=0.208,P<0.05) and lgG (r=0.163,P<0.05),and significantly negatively correlated with complementC3 (r=-0.201,P<0.05) and C4 (r=-0.227,P<0.05).Compared with patients without organ damage (Occult lupus),the CD4+CD25+Foxp3+T cells were increased in SLE patients with organ damage,especially those with skin involvement [10.9%(7.8%,13.1%),mean difference=56.93,P<0.05] and renal involvement [12.1%(9.1%,16.0%),mean difference=77.26,P<0.05].The proportion of CD4+CD25+Foxp3+T cells had no significant difference between SLE patients with treatments and patients with untreated new-onset lupus.The expressions of CTLA-4 [(53±15)%,t=7.04,P<0.01],GITR [(42±19)%,t=2.64,P<0.01] and ICOS [(28±9)%,t=4.27,P<0.01] on CD4+CD25+Foxp3+T cells were significantly lower in SLE patients than in healthy controls [CTLA-4 (71±4)%,GITR (53±10)% and ICOS (41±6)%].IL-17 synthesized by CD4+CD25+Foxp3+T cells in SLE patients [3.0%(1.8%,3.9%)] was significantly higher than that in healthy controls [1.0%(0.7%,1.2%),Z=-4.40,P<0.01].Conclusion The peripheral regulatory T cells are significantly increased in SLE patients and correlate with disease activity and organ damage.However,their inhibitory function is defective and they have more pro-inflammatory character-istics.
4.Correlation between serum 25 (OH)D values and disease activity of the treatment na?ve systemic lupus erythematosus patients
Jing ZHANG ; Jing LUO ; Jing WANG ; Jing HUANG ; Xiuyuan FENG ; Dan PU ; Xiaohong LYU ; Lan HE
Chinese Journal of Rheumatology 2019;23(1):36-41
Objective To explore the prevalence of vitamin D deficiency in the new onset and treatment-naive systemic lupus erythematosus (SLE) patients and study the correlation between serum 25(OH)D values and disease activity of SLE. Methods A retrospective case series analysis was done in 117 new-onset and treatment-na?ve SLE hospitalized patients during May 2016 and May 2017 in the Department of Rheumatology of the First Affiliated Hospital of Xi'an Jiaotong University and 39 age and gender matched healthy controls. Cinical and demographic details were collected. Disease activity of SLE was evaluated according to the systemic lupus erythematosus disease activity index (SLEDAI) score. The t-test, Mann-Whitney U test, Chi-square test, Spearman rank correlation coefficient test and multivariate linear regres sion were performed. Results Among the 117 SLE patients, 102 were female (87.2%) with the mean age of (36 ± 15) years. The median duration before diagnosis was 5(1, 12) months and the mean SLEDAI score was (12 ±7). The mean level of 25(OH)D was significantly lower in SLE patients [(10.1±6.0) ng/ml] than in healthy controls [(17 ±8) ng/ml, t=-5.273, P<0.01 ], and the prevalence of vitamin D deficiency was higher in SLE patients (109/117, 93.2%) than in healthy controls (28/39, 71.8%, x2=12.486, P<0.01). With 10 ng/ml as the cut-off point of serum 25 (OH)D, patients were divided into two groups. The percentages of haematological damage (84.3% vs 66.0%, x2=5.321, P=0.021), lupus nephritis (32.9% vs 14.9%, x2=4.759, P=0.029) and serositis (28.6% vs 8.5%, x2=6.940, P=0.008), SLEDAI score [(13±8) vs (9±5), t=3.503, P=0.001)] and 24-hour urinary protein [(0.57±1.05) vs (0.21±0.46), t=2.437, P=0.017] were significantly higher in the 25 (OH)D<10 ng/ml group, but complement C3 [(0.5±0.3) g/L vs (0.7±0.3) g/L t=-2.441, P=0.016] and hemoglobin [(93±19) g/L vs (104 ±19) g/L, t=-3.052, P=0.003) were significantly lower in this group. The differences were statistically significant. SLEDAI score (r=-0.433, P=0.000), 24-hour urinary protein (r=-0.434, P=0.000)was significantly inversely correlated and complement C3 (r=0.296, P=0.001), hemoglobin (r=0.323, P=0.000) was significantly positively correlated with serum 25(OH)D level. There was an independent inverse correlation between SLEDAI score and serum 25(OH)D levels (β=-0.376, P=0.000). Conclusion The prevalence of vitamin D deficiency in the new-onset and treatment-naive systemic lupus erythematosus patients is significantly higher than that in healthy controls. There is an independent inverse correlation between serum 25 (OH)D values and disease activity of SLE.
5.Correlation between memory B cells and bone erosion in rheumatoid arthritis
Li ZHU ; Nan HU ; Jing WANG ; Xiuyuan FENG ; Jing LUO ; Yanhua WANG ; Xiaohong LYU ; Dan PU ; Lan HE
Chinese Journal of Rheumatology 2023;27(3):151-157
Objective:To explore the distribution characteristics of memory B cells and its relationship with bone erosion in patients with rheumatoid arthritis (RA), and to further understand the mechanism of B cells in the pathogenesis of RA.Methods:B cell subsets in peripheral blood of 200 RA patients and 50 healthy individuals were detected by flow cytometry. According to the surface markers CD19, CD27 and lgD, B cells were divided into CD19 +CD27 +lgD - switched memory B cells, CD19 +CD27 +lgD + non-switched memory B cells, CD19 +CD27 -lgD - double-negative memory B cells and CD19 +CD27 -lgD + naive B cells. B cells in RA patients with various disease activity score, course of disease and treatment were analyzed. Patients were divided into four groups according to the results of joint ultrasonography, including patients without bone erosion, patients with hand bone erosion, patients with knee bone erosion and patients with hand and knee bone erosion. The relationship between the distribution of B cell subsets, autoantibodies and RA bone erosion were analyzed. Differences between the groups were analyzed by independent-samples t test, Mann-Whitney U test and χ2 test. The analysis of variance, Kruskal-Wallis analysis were used for multi-group comparison, Spearman correlation analysis was also used for correlation analysis. Results:①RA patients showed significantly decreased non-switched memory B cells [(9.5±6.7)% vs (12.1±4.7)%, t=2.46, P=0.015] and increased double negative memory B cells [(3.8±2.5)% vs(2.7±1.3)%, t=-4.74, P<0.001] in comparison to healthy individuals. The percentage of non-switched memory B cells were decreased in RA patients with moderate disease activity [(8.4±4.7 )% vs (12.4±7.5)%, t=3.13, P=0.001] and high disease activity [(7.8±7.6)% vs (12.4±7.5)%, t=3.00, P=0.003] in comparison to those in RA patients who achieved remission. Meanwhile, the na?ve B cells [(70.3±15.0)% vs (63.9±14.6)%, t=-2.15, P=0.034] were increased in RA patients with moderate disease activity. No difference was found in RA patients with different disease courses. Total B cells [(4.8±2.9)% vs (7.2±4.1)%, t=-3.24, P=0.001], non-switched memory B cells (7.6±4.3)% vs (10.0±7.1)%, t=-2.63, P=0.010) in RA patients who received prednisone treatment were decreased, while double-negative memory B cells (4.9±3.0)% vs (3.6±2.3)%, t=-2.79, P=0.006] were increased compared with those in RA patients without prednisone treatment. Non-switched memory B cells was decreased in RA patients with hand and knee erosion compared with RA patients without erosion [6.8%(2.5%, 9.5%) vs 9.7%(5.5%, 17.5%), Z=-2.12, P=0.034]. Double negative memory B cells in subgroup with keen erosion [3.3%(2.7%, 5.0%) vs 2.6%(1.9%, 3.8%), Z=-2.09, P=0.036]as well as with hand and knee erosion [3.9%(2.3%, 5.6%) vs 2.6%(1.9%, 3.8%), Z=-2.41, P=0.016] were higher than those in patients without erosion. In addition, higher serum RF level was found in subgroup RA patients with hand and knee erosion compared with subgroup of RA patients without erosion [141.0 (38.0, 874.0) U/ml vs 53.5 (10.0, 106.0)U/ml, Z=-2.07, P=0.039]. Meanwhile, the positive rate of ACPA in RA patients with bone erosion of hand was significantly higher than that of RA patients without bone erosion [81%(52/64) vs 64%(38/59), χ2=4.44, P=0.043). Conclusions:The results suggest that the increase of double negative memory B cells, the decrease of non-switched memory B cells and higher level of autoantibodies may closely relate to bone erosion of RA, which may be one of the pathogenesis of disability in RA.
6.Evaluation and characteristics of subclinical synovitis in patients with clinical remission of rheumatoid arthritis
Yanhua WANG ; Jing LUO ; Xiuyuan FENG ; Lingfei MO ; Dan PU ; Xiaohong LV ; Zhiming HAO ; Lan HE
Journal of Xi'an Jiaotong University(Medical Sciences) 2021;42(1):93-98
【Objective】 To evaluate musculoskeletal ultrasound (MSUS) detected subclinical synovitis of rheumatoid arthritis (RA) with different clinical remission criteria so as to explore the clinical characteristics of subclinical synovitis. 【Methods】 Forty-six consecutive patients with RA in clinical remission [disease activity score-28 (DAS28)≤2.6] underwent clinical and MSUS examinations at baseline and 1 year follow-up. Clinical remission was defined according to the DAS28 using the erythrocyte sedimentation rate (DAS28-ESR) and C-reactive protein level (DAS28-CRP), clinical disease activity index (CDAI), simplified clinical disease activity index (SDAI), and American College of Rheumatology/European League Against Rheumatism criteria Boolean (ACR/EULAR criteria). Subclinical synovitis was assessed by MSUS. Differences between the subclinical synovitis and non-subclinical synovitis groups were analyzed. 【Results】 The percentages of patients who achieved DAS28-ESR, DAS28-CRP, CDAI, SDAI, and ACR/EULAR remission at baseline and 1 year were 97.8%, 95.6%, 67.4%, 54.3%, 52.2% and 91.3%, 93.5%, 54.3%, 50.0%, and 45.6%, respectively. Subclinical synovitis was detected in 55.5%, 54.5%, 45.2%, 40.0%, 41.6% and 45.2%, 46.5%, 40.0%, 39.1%, and 38.1% of these patients, respectively. There were 45.6% and 41.3% patients who fulfilled all the criteria, yet 38.1% and 36.8% still had evidence of subclinical synovitis at baseline and 1 year. Compared with the patients without subclinical synovitis, those with subclinical synovitis had a significantly positive rate of anti-CCP antibody and a higher disease activity score at baseline (P<0.05). 【Conclusion】 MSUS detected subclinical synovitis is common. The positive anti-CCP antibody and higher disease activity score at baseline may be related to subclinical synovitis in patients with RA in clinical remission.